PAVmed
PAVM
70 hedge funds and large institutions have $10.9M invested in PAVmed in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 15 closing their positions.
385% more call options, than puts
Call options by funds: $228K | Put options by funds: $47K
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
0% more ownership
Funds ownership: 0.03% → 0.03% (+0%)
5% less capital invested
Capital invested by funds: $11.5M → $10.9M (-$528K)
4% less funds holding
Funds holding: 73 → 70 (-3)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$2.01M |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$1.26M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$298K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$211K |
| 5 |
Bank of New York Mellon
New York
|
+$47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.52M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.02M |
| 3 |
E
Ergoteles
New York
|
-$182K |
| 4 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$117K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$88K |
PAVM Hedge Fund Activity: Q3 2022 in Review
70 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q3 2022, worth a combined $10.9M — down 4.6% from $11.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of PAVM and 12 opened new positions — a net loss of 3 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was Ayrton Capital, opening a new position worth an estimated $2.01M. The largest seller was Millennium Management, cutting an estimated $1.52M.
- 70 institutional investors held PAVmed (PAVM) as of Q3 2022, down from 73 in Q2 2022.
- Funds reported $10.9M of PAVmed stock for Q3 2022, down 4.6% quarter-over-quarter.
- 12 funds opened new PAVmed positions in Q3 2022 and 15 closed out, a net change of -3 holders.
- The largest PAVmed buyer in Q3 2022 was Ayrton Capital, an estimated $2.01M added.
- The largest PAVmed seller in Q3 2022 was Millennium Management, an estimated $1.52M sold.
Based on aggregated 13F filings for Q3 2022.